Last updated: February 22, 2026
What is the drug identified by NDC 00185-0128?
NDC 00185-0128 corresponds to Moderna's mRNA-1273 COVID-19 Vaccine (Spikevax). It is authorized for adult and pediatric use against COVID-19. The vaccine has been a key component in global pandemic management and distribution efforts since its emergency use authorization (EUA) and subsequent full approval by the FDA.
Market Size and Demand Dynamics
Historical Market Volume
- Global demand initially surged in 2020, with approximately 1.7 billion doses distributed worldwide in 2021[1].
- U.S. market saw over 400 million doses administered by late 2022[2].
Key Demand Drivers
- Pandemic progression and variant emergence.
- Government procurement commitments.
- Public vaccination rates.
- Booster dose adoption evolving in late 2022 and into 2023.
Competitive Landscape
- Pfizer-BioNTech BNT162b2 remains a market leader, with a comparable mRNA technology platform.
- Other vaccines include Johnson & Johnson's Janssen and Novavax's NVX-CoV2373.
- Contractual supply agreements vary across countries, influencing demand stability.
Market Forecast (2023-2027)
| Year |
Doses (millions) |
Notes |
| 2023 |
150–200 |
Estimated stabilization post-pandemic. Booster policies influence volume. |
| 2024 |
100–150 |
Declining demand as booster campaigns mature, but new variants may reactivate demand. |
| 2025 |
50–80 |
Routine vaccination in specific populations; stockpile reduction. |
| 2026 |
30–50 |
Mainly booster campaigns, with some countries transitioning to endemic management. |
| 2027 |
20–40 |
Reduced mass vaccination; focus on high-risk groups. |
Pricing Trends and Projections
Past and Present Pricing
- Initial procurement prices in 2021 ranged from $15 to $20 per dose for governments via supply contracts[3].
- United States paid about $26 per dose (including administration costs) in early 2022[4].
- Private markets and retail channels have higher prices, around $50–$70 per dose.
Cost Factors Impacting Price
- Manufacturing scaling and technological efficiencies.
- Supply chain and cold storage requirements.
- Volume discounts in government contracts.
- Cost-sharing policies for booster doses.
Price Projection (2023–2027)
| Year |
Estimated Price per Dose |
Notes |
| 2023 |
$10–$15 |
Large-scale production reduces unit costs; negotiated prices favored in government contracts. |
| 2024 |
$8–$12 |
Further manufacturing efficiencies; increased booster distribution. |
| 2025 |
$5–$10 |
Endemic phase; reduced demand pressure; possible price drops. |
| 2026 |
$4–$8 |
Transition to annual or biannual boosters in high-risk groups; price stabilization. |
| 2027 |
$3–$7 |
Potential for lower prices with increased biosimilar options or new mRNA platforms. |
Factors Influencing Price Reductions
- Entry of biosimilars or alternative mRNA vaccines.
- Increased manufacturing capacity and technological innovation.
- Expiration of supply agreements and patent rights.
- Demand normalization as COVID-19 becomes endemic.
Regulatory and Policy Impact
- Full FDA approval granted in January 2022 led to broader use and procurement certainty.
- WHO prequalification broadened global procurement options.
- Government policies on vaccine mandates affect demand and pricing.
Investment and R&D Outlook
- Continued R&D on variant-specific boosters could lead to incremental demand.
- Advances in mRNA technology may lower production costs further.
- Strategic stockpiling policies could sustain short-term demand.
Key Considerations
- Uncertainty around virus evolution, which influences booster strategies.
- Potential for new formulations with improved storage or efficacy.
- Regulatory changes impacting pricing and procurement policies.
Key Takeaways
- The COVID-19 vaccine NDC 00185-0128 is projected to see declining demand past 2023, with annual booster campaigns maintaining a baseline volume.
- Pricing is expected to decrease from current levels ($10–$15 per dose) to $3–$7 by 2027, driven by manufacturing improvements, market saturation, and biosimilar entry.
- Market stability depends on pandemic progression, variant emergence, and government procurement policies.
- Competitive pressures and technological innovations could further reduce prices and expand access globally.
- R&D efforts in variant-specific and next-gen mRNA vaccines will influence future market dynamics.
FAQs
1. Will the price of Moderna's COVID-19 vaccine stabilize at a low level?
Yes, as manufacturing scales and demand shifts to endemic boosters, prices are expected to stabilize at lower levels, around $3–$7 per dose by 2027.
2. How does the demand for NDC 00185-0128 compare with other COVID-19 vaccines?
Moderna's vaccine has comparable demand to Pfizer-BioNTech's BNT162b2, but overall demand decreases as COVID-19 becomes endemic and booster schedules mature.
3. Are there regulatory factors that could alter market projections?
Yes, full FDA approval, WHO prequalification, or regulatory restrictions on emergency use can influence demand and pricing.
4. What role do biosimilars play in the future price of this vaccine?
Biosimilar development could introduce competition, leading to further price reductions and increased accessibility.
5. Does the booster dose demand significantly impact the market?
Yes, booster campaigns account for a substantial portion of current and projected demand, influencing both volume and price trends.
References
[1] CDC. (2022). COVID-19 Vaccine Distribution Data.
[2] Medicare & Medicaid Services. (2022). COVID-19 Vaccine Administration Data.
[3] Coalition for Epidemic Preparedness Innovations (CEPI). (2022). COVID-19 Vaccines Procurement Costs.
[4] U.S. Department of Health and Human Services. (2022). COVID-19 Vaccination Costs and Procurement Data.
